547 related articles for article (PubMed ID: 31696762)
1. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents.
Iglesias JF; Heg D; Roffi M; Tüller D; Lanz J; Rigamonti F; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
J Am Heart Assoc; 2019 Nov; 8(22):e013607. PubMed ID: 31696762
[TBL] [Abstract][Full Text] [Related]
2. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial.
Franzone A; Pilgrim T; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Räber L; Stortecky S; Wenaweser P; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Jun; 8(6):. PubMed ID: 26043895
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial.
Iglesias JF; Heg D; Roffi M; Tüller D; Noble S; Muller O; Moarof I; Cook S; Weilenmann D; Kaiser C; Cuculi F; Häner J; Jüni P; Windecker S; Pilgrim T
Circ Cardiovasc Interv; 2019 Aug; 12(8):e008024. PubMed ID: 31525083
[TBL] [Abstract][Full Text] [Related]
5. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients.
Roguin A; Kandzari DE; Marcusohn E; Koolen JJ; Doros G; Massaro JM; Garcia-Garcia HM; Bennett J; Gharib EG; Cutlip DE; Waksman R
Circ Cardiovasc Interv; 2018 Oct; 11(10):e007331. PubMed ID: 30354631
[TBL] [Abstract][Full Text] [Related]
6. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
[TBL] [Abstract][Full Text] [Related]
7. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
[TBL] [Abstract][Full Text] [Related]
8. Complex primary percutaneous coronary intervention with ultrathin-strut biodegradable versus thin-strut durable polymer drug-eluting stents in patients with ST-segment elevation myocardial infarction: A subgroup analysis from the BIOSTEMI randomized trial.
Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Windecker S; Pilgrim T
Catheter Cardiovasc Interv; 2023 Mar; 101(4):687-700. PubMed ID: 36807456
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents and Thin, Durable-Polymer Everolimus-Eluting Stents in Calcified or Small Vessel Lesions.
Dan K; Garcia-Garcia HM; Kolm P; Windecker S; Saito S; Kandzari DE; Waksman R
Circ Cardiovasc Interv; 2020 Sep; 13(9):e009189. PubMed ID: 32895004
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable polymer-coated thin strut sirolimus- -eluting stent versus durable polymer-coated everolimus-eluting stent in the diabetic population.
Gasior P; Gierlotka M; Szczurek-Katanski K; Osuch M; Roleder M; Hawranek M; Wojakowski W; Polonski L
Cardiol J; 2021; 28(2):235-243. PubMed ID: 31909473
[TBL] [Abstract][Full Text] [Related]
11. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial.
Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Muller O; Moarof I; Siontis GCM; Cook S; Weilenmann D; Kaiser C; Cuculi F; Hunziker L; Eberli FR; Jüni P; Windecker S
Lancet; 2018 Sep; 392(10149):737-746. PubMed ID: 30170848
[TBL] [Abstract][Full Text] [Related]
12. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
[TBL] [Abstract][Full Text] [Related]
14. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes.
Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
JACC Cardiovasc Interv; 2022 Sep; 15(18):1852-1860. PubMed ID: 36137689
[TBL] [Abstract][Full Text] [Related]
15. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
Waksman R; Shlofmitz E; Windecker S; Koolen JJ; Saito S; Kandzari D; Kolm P; Lipinski MJ; Torguson R
Am J Cardiol; 2019 Oct; 124(7):1020-1026. PubMed ID: 31353004
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
Pilgrim T; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Losdat S; Eeckhout E; Valgimigli M; Jüni P; Windecker S; Iglesias JF
JACC Cardiovasc Interv; 2021 Mar; 14(6):639-648. PubMed ID: 33727005
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Khattab AA; Taniwaki M; Rigamonti F; Nietlispach F; Blöchlinger S; Wenaweser P; Jüni P; Windecker S
EuroIntervention; 2016 Dec; 12(11):e1343-e1354. PubMed ID: 26690319
[TBL] [Abstract][Full Text] [Related]
19. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
Iglesias JF; Heg D; Roffi M; Degrauwe S; Tüller D; Muller O; Brinkert M; Cook S; Weilenmann D; Kaiser C; Cuculi F; Valgimigli M; Jüni P; Windecker S; Pilgrim T
Cardiovasc Revasc Med; 2022 Jan; 34():3-10. PubMed ID: 33653633
[TBL] [Abstract][Full Text] [Related]
20. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial.
Iglesias JF; Muller O; Losdat S; Roffi M; Kurz DJ; Weilenmann D; Kaiser C; Heg D; Valgimigli M; Windecker S; Pilgrim T
Int J Cardiol; 2021 Jul; 334():37-41. PubMed ID: 33887341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
